AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03728270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Specific Titanium Eminoplasty
Description: * The stages of virtual surgical planning and fabrication of patient specific titanium eminoplasty will be designed my Mimics 15 program.~* Once designed, the virtual design and surgery will be planned on a computer model where vital anatomical structures could be identified and thus could be avoided during surgery.~* After obtaining all the dataset needed from the CT scan, the collected data will be sent to the Egyptian soil, water and environmental institution for manufacturing, packing and sterilization of the patient specific titanium eminence.~* The patient specific titanium eminence will be inserted and secured with two to three screws of individual lengths according to the virtual plan.~* Functional mandibular movements were reproduced to confirm absence of subluxation and checked for interference and any required adjustments made.~* A multilayer closure of the incisions will be accomplished using Vicryl
Study NCT03728270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inlay Autogenous Bone Graft
Description: \* Steps to harvest the bone graft:~* Down-fracture of the articular eminence to be augmented with Inlay bone graft to increase the vertical height of the articular eminence. A green-stick fracture will be created avoiding a possible complete fracture of the lower segment of the eminence~* To obtain Inlay bone graft from the chin, anterior mandibular vestibule incision will provide good access to the mandibular symphysis.
Study NCT02931253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.
Study NCT04256863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast / Lunch
Description: Participants in the BFL group will participate in 16 weekly, group based sessions weekly sessions in which they will be exposed to standard behavioral therapy (SBT) for weight control. Each 90-minute session will cover one weight control topic (self-monitoring, modifying the home food environment, physical activity, goal setting, stimulus control, stress-related eating, motivation, problem solving, healthy eating on a budget, social influences and weight loss maintenance) and an experiential learning activity. These hands-on activities will help teens build skills to adhere to 1) their calorie goal (1,400 - 1,600 calories/day) and 2) the prescribed timing for consumption (>50% of their energy needs consumed before 3PM every day of the week. Sample meal plans will be provided to help with adherence. .
Study NCT04256863 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dinner (DIN)
Description: Participants randomized to the Dinner (DIN) group will participate in the same 16-week intervention as those in the BFL group; however, the topics covered in the experiential learning session will pertain to skills needed to adhere to prescribed calorie goals NOT to timing. They will be instructed to consume >50% of their energy needs after 3PM daily.; however, given that most teens consume the bulk of their calories after 5PM, the focus will be on general calorie goals vs. timing., Teens in this group will also be provided sample meal plans that outline how to spread out their calorie intake across breakfast (200), lunch (300), after school snack (200 calories), Dinner (700 calories), after dinner snack (200 calories for 1,600 calorie diet only).
Study NCT01048697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):~40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)
Study NCT02506751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liothyronine
Description: All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
Study NCT01133223 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penumbra™ System
Description: Patients assigned to the Thrombectomy arm will be conducted to the angio suite. Mechanical thrombectomy will be attempted with the use of the Penumbra™ System, and can be assisted by intraarterial thrombolysis (rTPA up to 20 mg)
Study NCT01133223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant tissue plasminogen activator
Description: Patients assigned to Usual Care arm will be thrombolysed according to the NINDS protocol (rtPA 0,9 mg/kg, 10% IV bolus and remaining in the next hour, up to 90 mg)
Study NCT02952196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drug administration
Description: administering drug to patient with amphetamine addiction
Study NCT02952196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: drug administration
Description: administering drug to patient with amphetamine addiction
Study NCT02167919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microspheres
Description: Prostatic artery embolization (PAE) is a new procedure that decreases the size of the prostate by blocking its arterial blood flow. Through a tiny puncture in the upper thigh or forearm a catheter is directed to the prostatic artery using fluoroscopic guidance. Once in place, sub-millimeter particles are injected that obstruct the prostatic arteries resulting in gland ischemia, and ultimately, reduction in size. The technique has only been recently developed in Portugal and Brazil and has similarities to Uterine Artery Embolization used to treat uterine fibroids.
Study NCT03177239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.~Storage Condition: 2 to 8°C. Protect from light and freezing.
Study NCT03177239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
Study NCT01178008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Description: Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints which are empirical for treating depression in term of traditional Chinese medicine theory. It is done by a registered Chinese medicine practitioner with at least 3 years experience of providing acupuncture treatment. An electric-stimulator is connected to these needles to give an electric-stimulation in a continuous wave The needles will be left for 30 min and then removed. Acupuncture treatment will consist of two sessions per week for 4 consecutive weeks.
Study NCT01178008 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture
Description: Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
Study NCT03664440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nevirapine
Description: Patients were randomized 1:1 to continuation arm (NVP-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
Study NCT03664440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilpivirine
Description: Patients were randomized 1:1 to switch arm (NVP-based regimens were switched to RPV-based regimens). Tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) remained as the backbone of the regimens.
Study NCT04278027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: CIRCuiTS is a web-based computerised CR therapy, delivered by a therapist but supplemented with independent sessions to facilitate massed practice. It targets metacognition, particularly strategy use, in addition to providing massed practice of basic cognitive functions. The therapist facilitates motivation, metacognitive and strategy development and generalisation of learning by encouraging the participant to learn about and regulate their cognitive performance and to transfer this learning to meet real-world goals. Therapists provide additional scaffolding for CR tasks to ensure consistent successful performance. Independent sessions involve carrying out cognitive tasks allocated by the therapist to ensure scaffolded learning (Reeder et al.2017)
Study NCT01987895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadazolid
Description: Cadazolid 250 mg as oral suspension twice daily.
Study NCT01987895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Vancomycin 125 mg as oral capsules 4 times daily.
Study NCT01987895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cadazolid-matching placebo
Description: Placebo matching cadazolid and administered orally twice daily
Study NCT01987895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin-matching placebo
Description: Placebo capsules matching vancomycin and administered orally 4 times per day
Study NCT05108753 — intervention group
Intervention type: OTHER
Intervention: Procedure/Surgery
Description: Transanal Total Mesorectal Excision
Study NCT02974400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based, CBT-oriented, guided self-help
Description: The self-help program includes sessions regarding (1) cognitive model, (2) sleep hygiene, (3) mindfulness, (4) meta-cognition, (5) coping with voice hearing, (6) persecutory ideation, (7) worrying, (8) self-esteem, (9) depression, (10) social competence, and (11) relapse prevention.
Study NCT02947100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCD-Omegatex™
Description: Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a 3+3 design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose.
Study NCT01336049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: Nimotuzumab 200mg/week
Study NCT01907867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days
Study NCT01883661 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BMMNC
Description: Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
Study NCT01557868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hylan G-F 20
Description: Three 2 cc injections at weekly intervals
Study NCT01557868 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1% sodium hyaluronate
Description: Three 2 cc injections at weekly intervals
Study NCT04288427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Patients who are candidates to receive 5ARI therapy, Finasteride, for clinical medical management of lower urinary tract symptoms will begin treatment once deemed eligible. They will be assess every 6 months for changes in urinary symptom scores and their responsiveness to the Finasteride treatment will be assessed at the 12-month time point. MRIs of prostate taken at the start of study and at the 3 year time point will assess prostate size and changes in size as well as degree of inflammatory changes. Gene expression of SRD5A2 as well as methylation pattern will be tested on prostate tissue samples, where hormonal androgen/estrogen levels will also be assessed as they are in blood samples.
Study NCT01593449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community-based social networking intervention
Description: Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
Study NCT01593449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based social networking intervention
Description: Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
Study NCT02383303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Development Account and financial education
Description: The Program intervention includes a matched savings account (Individual Development Account) and financial education.
Study NCT01998347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Study NCT01998347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study NCT01998347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01998347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Study NCT01315288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One of 6 video presentation by one of 4 presenters
Study NCT04525040 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProbioKid®
Description: Probiokid formulation includes three probiotic strains and fructooligosaccharides.
Study NCT04525040 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pragmatic comparator
Description: Standard of care as usual without a preventive intervention
Study NCT02969083 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNU
Description: Radical surgical removal by open or laparoscopic access
Study NCT02969083 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine/Cisplatin
Description: Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1
Study NCT02969083 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: M-VAC Protocol
Description: Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
Study NCT03932916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Pamoate for Injection 17mg
Description: A dosage of 17mg HHT201 will be injected into the muscle in the gluteus once.
Study NCT03932916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Pamoate for Injection 34mg
Description: A dosage of 34mg HHT201 will be injected into the muscle in the gluteus once.
Study NCT03932916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride 5mg
Description: A tablet of 5mg Donepezil Hydrochloride will be administered once.
Study NCT03145103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT ASPHINA 409
Description: intraocular lens
Study NCT03648138 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sugary drink warning labels
Description: This information appears in the description of the study arms.
Study NCT03648138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugary drink warning labels
Description: This information appears in the description of the study arms.
Study NCT03511690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRCA-Gist
Description: BRCA-gist is an innovative Intelligent Tutoring System intervention that uses avatars to emulate tailored one-to-one human tutoring and includes the bottom-line meaning of risk messages. BRCA-gist is designed to provide the same information contained in four modules from the NCI webpages: breast cancer and metastasis, risk factors, genetic mutation testing, and the consequences of testing.
Study NCT02993523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Solution for subcutaneous or intravenous administration.
Study NCT02993523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Solution for subcutaneous or intravenous administration.
Study NCT02993523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Tablet
Study NCT05495529 — intervention group
Intervention type: PROCEDURE
Intervention: Thermal Ablation
Description: Data collection about complications, succes of the procedure, succes of complete treatement, recurrence, biologic pertubations.
Study NCT04261647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio-taping techniques.
Study NCT04261647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercise
Study NCT04261647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.
Study NCT04261647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy program , stretching of piriformis. iliopsoas, clam shell exercise,seat cushioning and seat kitz.
Study NCT00683761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131I-TM601
Description: In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
Study NCT03634527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Point Acupressure
Description: Light touch using vaccaria seeds on specific points of the ear
Study NCT02993523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study NCT02954978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: 25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
Study NCT03634527 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Auricular Point Acupressure-
Description: Light touch using vaccaria seeds on different points of the ear (compared to the APA group).
Study NCT02447770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mars Cocoa Extract Capsules
Description: Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
Study NCT01908309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iobitridol 350
Study NCT02954978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib 150mg oral capsule [Tasigna]
Description: 25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
Study NCT02954978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib 300mg oral capsule [Tasigna]
Description: 25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
Study NCT03952078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-818
Description: Interleukin-2 inducible T-cell Kinase Inhibitor
Study NCT01296555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive fulvestrant 500 milligrams (mg) via intramuscular injection (as per package insert or Summary of Product Characteristics \[SmPC\]) on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent cycle, until disease progression (Cycle length: 28 days).
Study NCT01296555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Participants will receive GDC-0032 at escalating (Phase I, Stage 1) or fixed (Phase II and Phase I, Stage 2) doses until disease progression. Cycle 1 may be 35 days in length to allow for a 7-day washout following the initial dose; thereafter, GDC-0032 will be administered orally once daily in 28-day cycles.
Study NCT01296555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Participants will receive letrozole 2.5 mg orally (as per Package Insert or SmPC) once daily in 28-day cycles until disease progression.
Study NCT01296555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participants will receive midazolam 5 mg (as per Package Insert or SmPC) in hydrochloride syrup on Days 1 and 16 of Cycle 1.